FDA records indicate that there are no current recalls for this drug.
Are you a medical professional?
Trending Topics
Spectinomycin Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
INIDICATIONS FOR USE
SPECTAM® (spectinomycin) Injectable is for use in turkey poults and baby chicks as shown below:
Poults-
1. As an aid in the control of Chronic Respiratory Disease (CRD) associated with E. coli.
2. As an aid in the control of airsacculitis associated with Mycoplasma meleagridis sensitive to spectinomycin.
Chicks-
As an aid in the control of mortality and to lessen severity of infections caused by M. synoviae, S.typhimurium, S. infantis and E. coli.
SPECTAM® Injectable is intended only for subcutaneous injection. The injection should be made under the loose skin on the top of the neck halfway between the head and the base of the neck. Thoroughly clean and sterilize syringes and needles before using (needles and syringes may be sterilized by boiling in water for 15 minutes).
Use all precautions to prevent contamination of contents of bottle. Injection site should be disinfected with a suitable disinfectant such as 70% isopropyl alcohol just prior to injecting SPECTAM®.
DOSAGE
Directions
Poults-
1. As an aid in the control of Chronic Respiratory Disease (CRD) associated with E. coli, inject newly-hatched turkey poults with 5 mg of spectinomycin subcutaneously. See dilution table below for 5 mg concentration in saline solution.
2. As an aid in the control of airsacculitis associated with Mycoplasma meleagridis sensitive to spectinomycin, inject newly-hatched turkey poults with 0.1 mL (10 mg) of spectinomycin subcutaneously.
Chicks-
As an aid in the control of mortality and to lessen severity of infections caused by M. synoviae, S. typhimurium, S. infantis and E coli, inject newly-hatched chicks subcutaneously with SPECTAM® Injectable diluted with sterile physiological saline solution to provide 2.5 to 5.0 mg of spectinomycin in a 0.2 mL dose. See dilution table below for 2.5 mg or 5.0 mg concentration in saline solution.
Dilution Table to administer SPECTAM® Injectable containing 100 mg/mL.
Caution: For large flock administration only utilizing appropriate equipment with aseptic techniques. Discard any diluted solution remaining.
History
There is currently no drug history available for this drug.
Other Information
EACH mL CONTAINS:
Spectinomycin ............................................. 100 mg (from spectinomycin dihydrochloride pentahydrate)
Sodium Metabisulfite ................................... 0.5 mg
Sodium Citrate Dihydrate ..............................10 mg
Benzyl Alcohol, as preservative.................... 9 mg
Water for Injection ..........................................q.s.
Also contains Citric Acid and may contain Sodium Hydroxide for pH adjustment.
WARNING: For use only in 1-3 day old turkey poults and newly-hatched chicks.
PRECAUTIONS: Rarely, some individuals who handle spectinomycin develop serious reactions involving skin, nails and eyes. Individuals who have experienced rash or other evidence of allergic reaction should avoid further contact with spectinomycin.
Restricted drug, use only as directed.
To assure sterility, there should be only one entry into the vial.
IMPORTANT: For indications for use and for complete dosage information, directions and precautions to be observed, read attached insert before using this product.
PRODUCT CHARACTERISTICS
SPECTAM® Injectable is a clear, sterile solution of spectinomycin (from spectinomycin dihydrochloride pentahydrate) intended for subcutaneous injection in newly-hatched baby chicks and turkey poults. It is stable under normal conditions of storage and possesses excellent flow characteristics that make possible the use of a fine-gauge needle for injection. Spectinomycin has an extremely low degree of toxicity. Subcutaneous injections of up to 50 mg per poult have caused no detectable ill effects. Doses of 90 mg per poult have produced transient ataxia and coma from which poults recovered in approximately four hours. Under post-mortem examination, no local tissue reaction has been observed following the injection of SPECTAM®.
WARNING: For use only in 1-3 day old turkey poults and newly-hatched chicks.
PRECAUTIONS: Rarely, some individuals who handle spectinomycin develop serious reactions involving skin, nails and eyes. Individuals who have experienced rash or other evidence of allergic reaction should avoid further contact with spectinomycin.
Restricted drug, use only as directed.
To assure sterility, there should be only one entry into the vial.
IMPORTANT: For indications for use and for complete dosage information, directions and precautions to be observed, read attached insert before using this product.
PRODUCT CHARACTERISTICS
SPECTAM® Injectable is a clear, sterile solution of spectinomycin (from spectinomycin dihydrochloride pentahydrate) intended for subcutaneous injection in newly-hatched baby chicks and turkey poults. It is stable under normal conditions of storage and possesses excellent flow characteristics that make possible the use of a fine-gauge needle for injection. Spectinomycin has an extremely low degree of toxicity. Subcutaneous injections of up to 50 mg per poult have caused no detectable ill effects. Doses of 90 mg per poult have produced transient ataxia and coma from which poults recovered in approximately four hours. Under post-mortem examination, no local tissue reaction has been observed following the injection of SPECTAM®.
Sources
Spectinomycin Manufacturers
-
Bayer Healthcare Llc
Spectinomycin | Mylan Institutional Inc.
The recommended starting dose of memantine hydrochloride tablets is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
Memantine hydrochloride tablets can be taken with or without food. If a patient misses a single dose of memantine hydrochloride tablets, that patient should not double up on the next dose. The next dose should be taken as scheduled. If a patient fails to take memantine hydrochloride tablets for several days, dosing may need to be resumed at lower doses and retitrated as described above.
Special Populations: Renal Impairment: A target dose of 5 mg twice daily is recommended in patients with severe renal impairment (creatinine clearance of 5 to 29 mL/min based on the Cockroft-Gault equation).
Hepatic Impairment: Memantine hydrochloride tablets should be administered with caution to patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].
Login To Your Free Account